USA. DEA, SAMHSA Extend COVID-19 Telemedicine Flexibilities For Prescribing Controlled Medications For Six Months While Considering Comments From the Public
USA. DEA, SAMHSA Extend COVID-19 Telemedicine Flexibilities For Prescribing Controlled Medications For Six Months While Considering Comments From the Public
Today, ahead of the expiration of the COVID-19 Public Health Emergency (PHE), the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) issued the “Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” —a temporary rule that extends telemedicine flexibilities adopted during the COVID-19 PHE.
The temporary rule will take effect on May 11, 2023, and extends the full set of telemedicine flexibilities adopted during the COVID-19 PHE for six months—through November 11, 2023. For any practitioner-patient telemedicine relationships that have been or will be established up to November 11, 2023, the full set of telemedicine flexibilities regarding prescription of controlled medications established during the COVID-19 PHE will be extended for one-year—through November 11, 2024. (SAMHSA, USA, 09.05.2023)
https://www.samhsa.gov/newsroom/press-announcements/20230509/dea-extend-covid19-telemedicine-flexibilities-prescribing-controlled-medications